All News

Found 95 articles

• Arcutis Appoints Patrick Burnett, M.D., Ph.D., FAAD, as Chief Medical Officer

  7/27/2020

  Experienced industry leader to head Arcutis’ clinical development programs Appointment aligns with Arcutis’ strategy of building a team with deep dermatology expertise Howard Welgus, M.D., FAAD to retire; elected to Arcutis’ Board of Directors WESTLAKE VILLAGE, Calif., July 27, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc . (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological

• Verrica Pharmaceuticals Announces Dr. Lawrence Eichenfield Joins Board of Directors

  7/23/2020

  – Leading pediatric dermatologist brings significant expertise in the treatment of skin diseases to help inform development of the Company’s product candidates –

• Verrica Pharmaceuticals Announces Clinical and Drug Development Leadership Changes

  7/23/2020

  New leadership strengthens expertise in Clinical, Chemistry, Manufacturing, and Controls (CMC), and Regulatory Affairs

• Verrica Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

  7/14/2020

  Complete Response Letter Requests Additional Chemistry, Manufacturing, and Controls (CMC) and Human Factors Information

• Warts Therapeutics Market: Physical Destruction to be Highly Lucrative Treatment Type

  7/10/2020

  According to the report, the global warts therapeutics market was valued at US$ 1.7 Bn in 2019.

• 

  FDA Action Alert: BioSpecifics and Endo, Eagle Pharma, and Verrica

  7/6/2020

  It’s a relatively slow month ahead for July in terms of PDUFA dates for the U.S. FDA. However, there are several dates pending throughout the month. Here’s a look at three for the next two weeks.

• VRCA Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Verrica Pharmaceuticals Inc. and Encourages Investors to Contact the Firm

  7/2/2020

   Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ: VRCA). Investors who purchased Verrica securities are encouraged to obtain additional information and assist the investigation by visiting the firm's si

• Verrica Pharmaceuticals Provides Regulatory Update on VP-102

  6/29/2020

  Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced that, on June 24, 2020, the Company received a letter from the U.S. Food and Drug Administration (FDA) as part of the FDA’s ongoing review of the Company’s New Drug Application (NDA) for VP-102 (cantharidin 0.7% topical solution)

• 

  Clinical Catch-Up: June 8-12

  6/15/2020

  It was a fairly busy week with clinical trial updates and announcements. Here’s a look.

• Verrica Pharmaceuticals Announces Positive Results from Two New Pooled Analyses of the Phase 3 CAMP Trials of VP-102 in Molluscum Contagiosum

  6/12/2020

  Verrica Pharmaceuticals Inc. today announced the presentation of new pooled data from two analyses of the Phase 3 CAMP trials of VP-102 (cantharidin 0.7% topical solution), Verrica’s lead product candidate for the treatment of molluscum contagiosum (molluscum). These data are available in poster format online by the American Academy of Dermatology for the 2020 annual meeting, which was previously scheduled for March 20-24 in Denver, Colorado.

• Verrica Pharmaceuticals Appoints Diem Nguyen, Ph.D., M.B.A., to its Board of Directors

  6/10/2020

  Global biopharmaceutical industry veteran brings significant commercial expertise and business acumen to help advance the Company’s medical dermatology portfolio

• Verrica Pharmaceuticals to Present at the Jefferies 2020 Healthcare Conference

  5/27/2020

  Verrica Pharmaceuticals Inc., a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, announced that Ted White, Verrica President and CEO, will virtually present at the Jefferies 2020 Healthcare Conference.

• Verrica Pharmaceuticals Reports First Quarter 2020 Financial Results

  5/7/2020

  Issuance of Letters Patent directed to the Composition, Methods and Systems for the Treatment of Cutaneous Disorders by the Japan Patent Office

• Verrica Pharmaceuticals to Present at the Bank of America Merrill Lynch Global Healthcare Conference and the RBC Capital Markets Global Healthcare Conference

  5/6/2020

  Verrica Pharmaceuticals Inc., a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, announced that Ted White, Verrica President and CEO, will virtually present at two upcoming virtual healthcare conferences.

• Verrica Pharmaceuticals to Participate in the 19th Annual Needham Virtual Healthcare Conference

  4/9/2020

  Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will virtually present at the 19th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2020 at 2:10 p.m. ET.

• Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results

  3/13/2020

  Verrica Pharmaceuticals Inc., a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, announced financial results for the fourth quarter ended December 31, 2019.

• Verrica Pharmaceuticals Secures $55 Million in Loan Facilities Led by Silicon Valley Bank

  3/11/2020

  Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced that it has entered into a mezzanine loan and security agreement with Silicon Valley Bank (“SVB”) and WestRiver Innovation Lending Fund VIII, L.P., pursuant to which the lenders have agreed to lend the Company up to $50.0 million in a series of term loans.

• Verrica Pharmaceuticals to Attend Several Upcoming Investor Conferences - Feb. 20, 2020

  2/20/2020

  Verrica Pharmaceuticals Inc. announced that Ted White, Verrica President and CEO, will attend several upcoming investor conferences in March.

• 

  BioSpace Movers and Shakers, Jan. 31

  1/31/2020

  Pharma and biotech companies strengthen their leadership teams and boards with this week's Movers & Shakers.

• Verrica Pharmaceuticals Announces the Hiring of Two Vice Presidents to Further Grow its Commercial Capabilities

  1/29/2020

  Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced the appointment of two new Vice Presidents in its Commercial Operations group to support the potential launch, if approved, of YCANTH™ (cantharidin 0.7% topical solution),